Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-28

Clinical Trial Update: Bosutinib For Autosomal Dominant Polycystic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of bosutinib for autosomal dominant polycystic kidney disease has completed, and results were posted in October 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bosutinib (bosutinib)

Snippet

Sponsor: Pfizer | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 2 | Status: COMPLETED | Results posted: 2015-10-28